IMCR Immunocore Holdings Ltd

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus rating of "Moderate Buy" from twelve brokerages, with an average 12-month price target of $61.00. Institutional investors own 84.5% of the company's stock, and recent quarterly results showed a beat on EPS but a miss on revenue. The company is a clinical-stage biotechnology firm developing immunotherapies for cancer and infectious diseases.

Hudson Bay Capital Management LP has reduced its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 12.5%, selling 49,382 shares and retaining 345,952 shares valued at approximately $10.86 million. This adjustment comes as Immunocore reported Q2 EPS of $0.02, exceeding estimates, though revenue of $103.7 million missed expectations despite a 29.2% year-over-year increase. Analysts currently rate Immunocore as a "Moderate Buy" with a consensus target price of $61.00.

Frazier Life Sciences Management L.P. has significantly increased its stake in Immunocore Holdings PLC (NASDAQ:IMCR) by 27.8%, now owning 384,782 shares valued at approximately $12.07 million. This move comes as Immunocore reported mixed Q2 earnings, beating EPS estimates but missing revenue projections despite strong year-over-year growth. The company maintains a "Moderate Buy" analyst rating and institutional investors hold 84.5% of its stock.

Eschler Asset Management LLP recently invested $1.26 million in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR), acquiring 40,000 shares. This investment represents 0.9% of their portfolio, making Immunocore their 25th largest holding. The company currently has a market capitalization of $1.86 billion, with hedge funds and institutional investors owning about 84.5% of the stock.

Bellevue Group AG significantly increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 99.9% in the second quarter, making it their 16th largest holding. Despite missing revenue forecasts, Immunocore posted a positive EPS of $0.02 and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $61.00. Institutional ownership in Immunocore is high at 84.5%, indicating strong investor confidence.

BVF Inc. IL has purchased 1,024,288 shares of Immunocore (NASDAQ:IMCR) in Q2, valuing its stake at $32.14 million and representing 2.04% ownership. Immunocore, a commercial-stage biotechnology company, reported an EPS beat but a revenue miss in its latest quarter, with analysts maintaining a "Moderate Buy" consensus rating and a $61 average price target. Institutional investors hold a significant 84.5% of the company's stock.